Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05324033
Other study ID # REC-FMHU 51/2021
Secondary ID
Status Completed
Phase
First received
Last updated
Start date May 1, 2022
Est. completion date April 1, 2023

Study information

Verified date March 2023
Source Helwan University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Differentiation between non-muscle-invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC) is a cornerstone in the treatment plans.Therefore, this study will try to evaluate the sensitivity and reliability of mpMRI in accurate diagnosis of cancer bladder. Primary objective: to detect the sensitivity of multiparametric MRI in differentiation between muscle Invasive and non-muscle invasive Urinary Bladder Cancer in relation to the conventional cystoscopy and histopathological examination of the biopsy.


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date April 1, 2023
Est. primary completion date February 1, 2023
Accepts healthy volunteers
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - All patients diagnosed with NMIBC or MIBC during diagnostic cystoscopy or by any radiologic investigation in the Urology department of Helwan university hospitals without being restricted to age or sex. - All histological types of bladder cancer - Newly diagnosed, recurrent cases, or even patients undergoing follow-up cystoscopy. Exclusion Criteria: - Patients with elevated renal function according to their age as this will be a contraindication to DCE MRI. - Patients with absolute contraindication to MRI (e.g.: metallic prosthesis). - Patients with contraindication to undergo TURBT (e.g.: unfit for surgery).

Study Design


Related Conditions & MeSH terms


Intervention

Radiation:
multiparametric MRI on the bladder
comparison between mpMRI and histopathology
Procedure:
diagnostic cystoscopy +/- TURBT
conventional way of diagnosis

Locations

Country Name City State
Egypt Faculty of medicine, Helwan university Badr Cairo

Sponsors (1)

Lead Sponsor Collaborator
Helwan University

Country where clinical trial is conducted

Egypt, 

References & Publications (24)

Bjurlin MA, Carroll PR, Eggener S, Fulgham PF, Margolis DJ, Pinto PA, Rosenkrantz AB, Rubenstein JN, Rukstalis DB, Taneja SS, Turkbey B. Update of the Standard Operating Procedure on the Use of Multiparametric Magnetic Resonance Imaging for the Diagnosis, Staging and Management of Prostate Cancer. J Urol. 2020 Apr;203(4):706-712. doi: 10.1097/JU.0000000000000617. Epub 2019 Oct 23. — View Citation

Bochner BH, Dalbagni G, Sjoberg DD, Silberstein J, Keren Paz GE, Donat SM, Coleman JA, Mathew S, Vickers A, Schnorr GC, Feuerstein MA, Rapkin B, Parra RO, Herr HW, Laudone VP. Comparing Open Radical Cystectomy and Robot-assisted Laparoscopic Radical Cystectomy: A Randomized Clinical Trial. Eur Urol. 2015 Jun;67(6):1042-1050. doi: 10.1016/j.eururo.2014.11.043. Epub 2014 Dec 8. — View Citation

Chang SS, Bochner BH, Chou R, Dreicer R, Kamat AM, Lerner SP, Lotan Y, Meeks JJ, Michalski JM, Morgan TM, Quale DZ, Rosenberg JE, Zietman AL, Holzbeierlein JM. Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline. J Urol. 2017 Sep;198(3):552-559. doi: 10.1016/j.juro.2017.04.086. Epub 2017 Apr 26. Erratum In: J Urol. 2017 Nov;198(5):1175. — View Citation

Chavhan, G. (2013). MRI Made Easy (for beginners) (2nd ed., pp. 2-16). JAYPEE BROTHERS MEDICAL PUBLISHERS (P) LTD.

Cheung G, Sahai A, Billia M, Dasgupta P, Khan MS. Recent advances in the diagnosis and treatment of bladder cancer. BMC Med. 2013 Jan 17;11:13. doi: 10.1186/1741-7015-11-13. — View Citation

DeGeorge KC, Holt HR, Hodges SC. Bladder Cancer: Diagnosis and Treatment. Am Fam Physician. 2017 Oct 15;96(8):507-514. — View Citation

Del Giudice F, Barchetti G, De Berardinis E, Pecoraro M, Salvo V, Simone G, Sciarra A, Leonardo C, Gallucci M, Catalano C, Catto JWF, Panebianco V. Prospective Assessment of Vesical Imaging Reporting and Data System (VI-RADS) and Its Clinical Impact on the Management of High-risk Non-muscle-invasive Bladder Cancer Patients Candidate for Repeated Transurethral Resection. Eur Urol. 2020 Jan;77(1):101-109. doi: 10.1016/j.eururo.2019.09.029. Epub 2019 Nov 5. — View Citation

Ghai S, Haider MA. Multiparametric-MRI in diagnosis of prostate cancer. Indian J Urol. 2015 Jul-Sep;31(3):194-201. doi: 10.4103/0970-1591.159606. — View Citation

Hawkes RC, Holland GN, Moore WS, Worthington BS. Nuclear magnetic resonance (NMR) tomography of the brain: a preliminary clinical assessment with demonstration of pathology. J Comput Assist Tomogr. 1980 Oct;4(5):577-86. doi: 10.1097/00004728-198010000-00001. — View Citation

Huang L, Kong Q, Liu Z, Wang J, Kang Z, Zhu Y. The Diagnostic Value of MR Imaging in Differentiating T Staging of Bladder Cancer: A Meta-Analysis. Radiology. 2018 Feb;286(2):502-511. doi: 10.1148/radiol.2017171028. Epub 2017 Dec 4. — View Citation

Kagawa T, Yoshida S, Shiraishi T et al., Basic principles of magnetic resonance imaging for beginner oral and maxillofacial radiologists. Oral Radiol 33, 92-100 (2017).

Kelly, C. R., & Landman, J. (2012, March 29). The Netter Collection of Medical Illustrations - Urinary System. saunders elsevier.

Margel D, Alkhateeb SS, Finelli A, Fleshner N. Diminished efficacy of Bacille Calmette-Guerin among elderly patients with nonmuscle invasive bladder cancer. Urology. 2011 Oct;78(4):848-54. doi: 10.1016/j.urology.2011.04.070. Epub 2011 Aug 16. — View Citation

Nikolaev A, Knipe H, Bell D. (2020). Vesical Imaging-Reporting and Data System (VI-RADS) | Radiology Reference Article | Radiopaedia.org. Vesical Imaging-Reporting and Data System (VI-RADS) | Radiology Reference Article | Radiopaedia.org. Retrieved January 27, 2023, from https://radiopaedia.org/articles/vesical-imaging-reporting-and-data-system-vi-rads-2

Oeyen E, Hoekx L, De Wachter S, Baldewijns M, Ameye F, Mertens I. Bladder Cancer Diagnosis and Follow-Up: The Current Status and Possible Role of Extracellular Vesicles. Int J Mol Sci. 2019 Feb 14;20(4):821. doi: 10.3390/ijms20040821. — View Citation

Petralia G, Summers PE, Agostini A, Ambrosini R, Cianci R, Cristel G, Calistri L, Colagrande S. Dynamic contrast-enhanced MRI in oncology: how we do it. Radiol Med. 2020 Dec;125(12):1288-1300. doi: 10.1007/s11547-020-01220-z. Epub 2020 May 15. — View Citation

Shampo MA, Kyle RA, Steensma DP. Richard Ernst--Nobel Prize for nuclear magnetic resonance spectroscopy. Mayo Clin Proc. 2012 Dec;87(12):e109. doi: 10.1016/j.mayocp.2012.01.023. No abstract available. — View Citation

Shariat SF, Sfakianos JP, Droller MJ, Karakiewicz PI, Meryn S, Bochner BH. The effect of age and gender on bladder cancer: a critical review of the literature. BJU Int. 2010 Feb;105(3):300-8. doi: 10.1111/j.1464-410X.2009.09076.x. Epub 2009 Nov 13. — View Citation

Standring, S., Anand, N., Birch, R., Collins, P., Crossman, A., & Gleeson , M. (2016). Anatomy GRAY'S The Anatomical Basis of Clinical Practice (41st ed., pp. 1254-1313). Elsevier Limited

Wang H, Luo C, Zhang F, Guan J, Li S, Yao H, Chen J, Luo J, Chen L, Guo Y. Multiparametric MRI for Bladder Cancer: Validation of VI-RADS for the Detection of Detrusor Muscle Invasion. Radiology. 2019 Jun;291(3):668-674. doi: 10.1148/radiol.2019182506. Epub 2019 Apr 23. — View Citation

Westbrook, C., Roth, C., & Talbot, J. (2011). MRI in Practice (4th ed., pp. 397-403). A John Wiley & Sons, Ltd., Publication.

Withey SJ, Christodoulou D, Prezzi D, Rottenberg G, Sit C, Ul-Hassan F, Carroll P, Velusamy A, Izatt L, Nair R, Jacques AET. Bladder paragangliomas: a pictorial review. Abdom Radiol (NY). 2022 Apr;47(4):1414-1424. doi: 10.1007/s00261-022-03443-2. Epub 2022 Feb 14. — View Citation

Woo S, Suh CH, Kim SY, Cho JY, Kim SH. Diagnostic performance of MRI for prediction of muscle-invasiveness of bladder cancer: A systematic review and meta-analysis. Eur J Radiol. 2017 Oct;95:46-55. doi: 10.1016/j.ejrad.2017.07.021. Epub 2017 Jul 29. — View Citation

Zhu CZ, Ting HN, Ng KH, Ong TA. A review on the accuracy of bladder cancer detection methods. J Cancer. 2019 Jul 8;10(17):4038-4044. doi: 10.7150/jca.28989. eCollection 2019. — View Citation

* Note: There are 24 references in allClick here to view all references

Outcome

Type Measure Description Time frame Safety issue
Primary to detect the sensitivity of multiparametric MRI in differentiation between muscle Invasive and non-muscle invasive Urinary Bladder Cancer in relation to the conventional cystoscopy and histopathological examination of the biopsy. 6 month
Secondary the sensitivity of mpMRI to detect non-visible lesions during follow up cystoscopy while mpMRI reports a positive lesion. 6 month
See also
  Status Clinical Trial Phase
Recruiting NCT03301493 - Genomic Testing and Resulting Medical Decisions
Completed NCT05278598 - 3 Ultrasound Guided Plane Blocks for Perioperative Analgesia in Patients Undergoing Radical Cystectomy N/A
Recruiting NCT03896958 - The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)
Not yet recruiting NCT05262166 - Opioid Free Anesthesia in Prolonged Surgery N/A
Completed NCT05822518 - Outcome of Perioperative Immune Enhancing Nutrition in Patients Undergoing Radical Cystectomy N/A